Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Seelos Therapeutics Inc News

    0,322 $ -3,01% -0,01 $
    In : 0,3027 € | 18.04.24 21:59:53 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3ESGY
    ISIN: US81577F2083
    US-Symbol: SEEL
    Typ: Aktie

    Unternehmensmeldungen

    03.05.18 - GlobeNewswire
    Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results:
    Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results: Company Pursuing U.S. Vitaros Partnership and Strategic Alternatives SAN DIEGO, May ...
    16.04.18 - GlobeNewswire
    Apricus Biosciences Announces Outcome of Vitaros(TM) End-of-Review Meeting with FDA
    Apricus Biosciences Announces Outcome of Vitaros(TM) End-​of-Review Meeting with FDA FDA Confirms Vitaros Regulatory Pathway Company Seeking Partner to Develop Vitaros ...
    28.03.18 - GlobeNewswire
    Apricus Biosciences Announces Pricing of $3.55 Million Public Offering
    Apricus Biosciences Announces Pricing of $3.55 Million Public Offering SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a ...
    27.03.18 - GlobeNewswire
    Apricus Biosciences Announces Proposed Public Offering
    Apricus Biosciences Announces Proposed Public Offering SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical ...
    26.03.18 - GlobeNewswire
    Apricus Biosciences Announces Scheduling of Vitaros(TM) End-of-Review Meeting with FDA
    Apricus Biosciences Announces Scheduling of Vitaros(TM) End-​of-Review Meeting with FDA Meeting Scheduled for April 12, 2018 SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) ...
    01.03.18 - GlobeNewswire
    Apricus Biosciences, Inc. : Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results
    Apricus Biosciences, Inc. : Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Company Expects to Submit Vitaros End of Review ...
    21.02.18 - GlobeNewswire
    Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call
    Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- ...
    16.02.18 - GlobeNewswire
    Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros(TM)
    Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros(TM) Company Evaluating Deficiencies and Potential Path Forward SAN DIEGO, Feb. 16, 2018 ...
    26.10.17 - GlobeNewswire
    Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call
    Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Apricus ...
    10.10.17 - GlobeNewswire
    Apricus Biosciences to Present at the 2017 BIO Investor Forum
    Apricus Biosciences to Present at the 2017 BIO Investor Forum SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical ...
    11.09.17 - GlobeNewswire
    Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market
    Apricus Biosciences Announces $3.7 Million Private Placement Priced At-​The-Market SAN DIEGO, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), ...
    05.09.17 - GlobeNewswire
    Apricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
    Apricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference SAN DIEGO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, ...
    31.08.17 - GlobeNewswire
    Apricus Biosciences Announces FDA Acknowledgement of Vitaros(TM) Class 2 NDA Resubmission
    Apricus Biosciences Announces FDA Acknowledgement of Vitaros(TM) Class 2 NDA Resubmission PDUFA Goal Date of February 17, 2018 SAN DIEGO, Aug. 31, 2017 (GLOBE ...
    29.08.17 - GlobeNewswire
    Apricus Biosciences Files NDA Resubmission for Vitaros(TM)
    Apricus Biosciences Files NDA Resubmission for Vitaros(TM) Approval Decision Expected in First Quarter 2018 SAN DIEGO, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Apricus ...
    02.08.17 - GlobeNewswire
    Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results
    Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results Vitaros Drug-​Device Human Factor Studies Successfully Completed Vitaros U.S. NDA ...
    26.07.17 - GlobeNewswire
    Apricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call
    Apricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call SAN DIEGO, July 26, 2017 (GLOBE NEWSWIRE) -- Apricus ...
    04.05.17 - GlobeNewswire
    Apricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study
    Apricus Biosciences Announces the Initiation of Vitaros Drug-​Device Human Factors Study Vitaros U.S. NDA Re-​Submission on Track for Third Quarter 2017 SAN DIEGO, May 04, ...
    04.05.17 - GlobeNewswire
    Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call
    Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Apricus ...
    02.05.17 - GlobeNewswire
    Apricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements
    Apricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements SAN DIEGO, May 02, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ...
    21.04.17 - GlobeNewswire
    Apricus Biosciences Announces Pricing of $7.0 Million Public Offering
    Apricus Biosciences Announces Pricing of $7.0 Million Public Offering SAN DIEGO, April 21, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a ...

    Newssuche

    Videos

    18.04.24
    Technical Trading: Gold mit weiterem Potenzial
    Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »